Axsome 治療公司
US ˙ NasdaqGM ˙ US05464T1043

SecurityAXSM / Axsome Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership70,118 shares
Latest Disclosed Value $ 7,319,618
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 11.75% increase in ownership of AXSM / Axsome Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 70,118 shares of Axsome Therapeutics, Inc. (US:AXSM) valued at $7,319,618 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 62,747 shares of Axsome Therapeutics, Inc.. This represents a change in shares of 11.75% during the quarter. The current value of the position is $16,289,814 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Axsome Therapeutics EC US05464T1043 70,118 7,371 11.75 7,320 0.01 0.1644
2025-05-28 2025-03-31 NP Axsome Therapeutics EC US05464T1043 62,747 666 1.07 7,318 39.34 0.1755
2025-02-25 2024-12-31 NP Axsome Therapeutics EC US05464T1043 62,081 -9,415 -13.17 5,253 -18.26 0.1147
2024-11-26 2024-09-30 NP Axsome Therapeutics EC US05464T1043 71,496 3,730 5.50 6,425 17.78 0.1215
2024-08-26 2024-06-30 NP Axsome Therapeutics EC US05464T1043 67,766 4,825 7.67 5,455 8.62 0.1111
2024-05-28 2024-03-31 NP Axsome Therapeutics EC US05464T1043 62,941 -1,124 -1.75 5,023 -1.49 0.1048
2024-02-26 2023-12-31 NP Axsome Therapeutics EC US05464T1043 64,065 4,402 7.38 5,099 22.28 0.1088
2023-11-28 2023-09-30 NP Axsome Therapeutics EC US05464T1043 59,663 2,755 4.84 4,170 1.96 0.1088
2023-08-25 2023-06-30 NP Axsome Therapeutics EC US05464T1043 56,908 6,028 11.85 4,089 30.31 0.0970
2023-05-26 2023-03-31 NP Axsome Therapeutics EC US05464T1043 50,880 634 1.26 3,138 -19.02 0.0836
2023-02-24 2022-12-31 NP Axsome Therapeutics EC US05464T1043 50,246 3,995 8.64 3,875 87.83 0.1066
2022-11-25 2022-09-30 NP Axsome Therapeutics EC US05464T1043 46,251 0 0.00 2,064 16.49 0.0591
2022-08-25 2022-06-30 NP Axsome Therapeutics EC US05464T1043 46,251 2,531 5.79 1,771 -2.10 0.0489
2022-05-26 2022-03-31 NP Axsome Therapeutics EC US05464T1043 43,720 1,621 3.85 1,810 13.77 0.0422
2022-02-25 2021-12-31 NP Axsome Therapeutics EC US05464T1043 42,099 0 0.00 1,590 14.64 0.0345
2021-11-24 2021-09-30 NP Axsome Therapeutics EC US05464T1043 42,099 0 0.00 1,388 -51.14 0.0306
2021-08-26 2021-06-30 NP Axsome Therapeutics EC US05464T1043 42,099 -104 -0.25 2,840 18.84 0.0609
2021-05-27 2021-03-31 NP Axsome Therapeutics EC US05464T1043 42,203 -1,236 -2.85 2,390 -32.48 0.0542
2021-02-25 2020-12-31 NP Axsome Therapeutics EC US05464T1043 43,439 -1,912 -4.22 3,539 9.50 0.0907
2020-11-25 2020-09-30 NP Axsome Therapeutics EC US05464T1043 45,351 -1,550 -3.30 3,231 -16.27 0.1037
2020-08-27 2020-06-30 NP Axsome Therapeutics EC US05464T1043 46,901 1,858 4.12 3,859 45.68 0.1261
2020-06-01 2020-03-31 NP Axsome Therapeutics EC US05464T1043 45,043 5,934 15.17 2,650 -34.46 0.1083
2020-02-27 2019-12-31 NP Axsome Therapeutics EC 05464T104 39,109 1,931 5.19 4,042 437.50 0.1216
2019-11-27 2019-09-30 NP Axsome Therapeutics EC US05464T1043 37,178 37,178 752 0.0249
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.